Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Orca Bio Reports Positive Phase 3 Results for Orca-T in Hematologic Cancers
Details : Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of acute myeloid leukemia.
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Orca-T,Tacrolimus
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orca Bio’s Orca-T Shows Positive Phase 3 Data in Hematologic Malignancies
Details : Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of acute myeloid leukemia.
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Orca-T,Tacrolimus
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orca-T Meets Primary Endpoint in Phase 3 Precision-T Hematologic Study
Details : Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of advanced hematologic malignancies.
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 10, 2025
Orca Bio Completes Enrollment for Precision-T Phase 3 Study
Details : Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies, such as AML.
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 05, 2024
Details : Orca-Q is an investigational allogeneic cellular therapy consisting of a single infusion containing a proprietary composition of stem and immune cells derived from peripheral blood from either related or unrelated matched, unmatched or haploidentical don...
Product Name : OrcaGraft
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 03, 2022
Details : TregGraft (Orca-T) is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched do...
Product Name : TregGraft
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 02, 2022
Orca Bio to Present New Clinical Data on Orca-T at the European Hematology Association 2022 Congress
Details : TregGraft (Orca-T) , an investigational, high-precision allogeneic cell therapy derived from stem and immune cells from either related or unrelated HLA-matched donors, is intended to safely replace a patient’s compromised blood and immune system with t...
Product Name : TregGraft
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 12, 2022
Details : Pooled data from 137 patients show Orca-T, an investigational high-precision allogeneic cellular therapy improved overall survival and reduced chronic graft versus host disease compared to standard of care.
Product Name : TregGraft
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 25, 2022
Lead Product(s) : TregGraft
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Early multi-center results indicate that Orca-T, a novel approach to HSCT, improves time-to-engraftment, markedly reduces the incidence and severity of GvHD, and significantly improved GRFS at 1 year.
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 06, 2020
Lead Product(s) : TregGraft
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TregGraft
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary data from the Phase I/II clinical trials of Orca-T will be presented at the 62nd American Society of Hematology Annual Meeting. Data provide insights into manufacturing efficiency, logistics and early clinical outcomes of Orca-T for patients ...
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 04, 2020
Lead Product(s) : TregGraft
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable